Day 1 – Sept 23, 2026 - ET (Eastern Time, GMT-05:00)
Identifying high-growth regions and market opportunities
Navigating regulatory landscapes and compliance challenges
Building strategic partnerships to accelerate market entry
- Renee Aguiar-Lucander - Chief Executive Officer, Hansa Biopharma
- Mike Patten - Chief Strategy Officer, Harbour BioMed
How prioritizing IPOs, M&A, or revenue, changes governance, hiring, and program selection compared with goals like platform enablement, open science, or measurable patient outcomes
Examining how investor horizons, deal structures and funding mixes shape R&D priorities and whether they align or conflict with longterm societal goals
Access vs. scale: does commercialization reliably increase patient access or create affordability barriers?
- Mark Cabato - Chief Business Officer, Immunis Inc
Navigating limited patient populations and high development costs
Building awareness and education among healthcare providers
Leveraging orphan drug incentives and regulatory support
- Jennifer Schranz - SVP Global Head of Rare Diseases, Ipsen
- Julie Carnis - VP and Head of Rare Oncology, SERB Pharmaceuticals
- Vanessa Wolfeler - Chief Executive Officer, Board member, SERB Pharmaceuticals
Managing supply chain complexities and ensuring scalability
Aligning cross-functional teams for seamless execution
Balancing cost efficiency with quality and compliance
- Anna Argo - CBO, Cytotheryx
- Rachel Ravens - CEO, 42Genetics
- Raven Lin - CEO, Pilatus Biotechnologies